SCHEMBL280236

SCHEMBL280236

NNC(=O)c1ccc(C(=O)NCC(=O)O)s1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.67
TDP1 Q9NUW8 2/20 0.67
KMT2A Q03164 1/20 0.67
KDM4E B2RXH2 4/20 0.49
MAPT P10636 2/20 0.49
HIF1A Q16665 1/20 0.49
SLC22A6 Q4U2R8 1/20 0.49
SLC22A8 Q8TCC7 1/20 0.49
ALDH1A1 P00352 3/20 0.46
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
USP5 P45974 1/20 0.43
HDAC4 P56524 3/20 0.42
HDAC1 Q13547 3/20 0.42
HDAC6 Q9UBN7 3/20 0.42
GAA P10253 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
HDAC3 O15379 2/20 0.42
HPGDS O60760 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL276955 0.84 ALDH1A1 (0.58) POLBTDP1KMT2AKDM4EMAPT
SCHEMBL277890 0.82 KMT2A (0.55) POLBTDP1KMT2AKDM4EMAPT
SCHEMBL14625162 0.80 POLB (0.45) POLBTDP1KMT2AKDM4EMAPT
SCHEMBL2638143 0.80 ALDH1A1 (0.51) POLBTDP1KMT2AKDM4EMAPT
SCHEMBL280023 0.80 POLB (1.00) POLBTDP1KMT2AMAPTALDH1A1
SCHEMBL14986443 0.80 GAA (0.67) POLBTDP1KMT2AKDM4EMAPT
SCHEMBL1106560 0.80 KMT2A (0.65) POLBTDP1KMT2AKDM4EALDH1A1
SCHEMBL14986345 0.80 POLB (0.65) POLBTDP1KMT2AKDM4EMAPT
SCHEMBL12313375 0.77 KMT2A (0.66) POLBTDP1KMT2AKDM4EMAPT
SCHEMBL13402903 0.77 POLB (0.61) POLBTDP1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8026368-B2 Hydrazide compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2011-09-27 US disclosed
US-8026368-B2 Hydrazide compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2011-09-27 US disclosed
US-20090253751-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-10-08 US disclosed
US-20090253751-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-10-08 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL POLB 4352/4885TDP1 2969/4885KMT2A 3398/4885
US-20090253751-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, THPO, PTAFR POLB 3909/4885TDP1 2408/4885KMT2A 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.